ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) will likely be posting its quarterly earnings results on Monday, March 24th. Analysts expect ProMIS Neurosciences to post earnings of ($0.14) per share for the quarter.
ProMIS Neurosciences Trading Down 2.6 %
Shares of PMN stock opened at $0.65 on Friday. The business’s 50 day moving average is $0.85 and its two-hundred day moving average is $0.98. ProMIS Neurosciences has a twelve month low of $0.62 and a twelve month high of $2.61. The company has a market capitalization of $21.08 million, a P/E ratio of -6.45 and a beta of 0.58.
Wall Street Analyst Weigh In
Separately, Guggenheim reiterated a “buy” rating on shares of ProMIS Neurosciences in a research note on Wednesday, February 26th.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Further Reading
- Five stocks we like better than ProMIS Neurosciences
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Why Are These Companies Considered Blue Chips?
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
- 3 Healthcare Dividend Stocks to Buy
- MarketBeat Week in Review – 03/17 – 03/21
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
